Janux Therapeutics Inc

JANX

13.070USD

+0.890+7.31%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Janux Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

32 / 392

Overall Ranking

129 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Janux Therapeutics Inc Highlights

StrengthsRisks

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.94% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.59M.

Overvalued

The company’s latest PE is -7.79, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 66.35M shares, decreasing 11.56% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.90M shares of this stock.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

60.750

Target Price

+398.77%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Janux Therapeutics Inc is 8.58, ranking 39 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 10.00M, representing a year-over-year increase of 2177.90%, while its net profit experienced a year-over-year increase of 13.35%.

Score

Industry at a Glance

Previous score

8.58

Change

0



Financials

7.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Janux Therapeutics Inc is 7.76, ranking 81 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.79, which is -48.76% below the recent high of -3.99 and -633.02% above the recent low of -57.11.

Score

Industry at a Glance

Previous score

7.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 32/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Janux Therapeutics Inc is 8.50, ranking 105 out of 392 in the Biotechnology & Medical Research industry. The average price target is 53.50, with a high of 200.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Janux Therapeutics Inc is 6.64, ranking 207 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 15.00 and the support level at 11.63, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.19

Change

0.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Janux Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 110.31%, representing a quarter-over-quarter decrease of 1.18%. The largest institutional shareholder is The Vanguard, holding a total of 2.90M shares, representing 4.82% of shares outstanding, with 25.60% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

11.19M

--

Fidelity Management & Research Company LLC

8.45M

-2.08%

Janus Henderson Investors

4.70M

+5.40%

BlackRock Institutional Trust Company, N.A.

3.21M

+10.19%

Bregua Corp

3.00M

-21.68%

Paradigm BioCapital Advisors LP

2.92M

--

The Vanguard Group, Inc.

Star Investors

2.41M

+10.44%

Adage Capital Management, L.P.

2.77M

+9.90%

State Street Investment Management (US)

1.89M

+36.26%

OrbiMed Advisors, LLC

1.77M

+45.92%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Janux Therapeutics Inc is 2.93, ranking 186 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Janux Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Janux Therapeutics Inc

JANX

7.63 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment